Neimeth International Pharmaceuticals Plc’s roots can be traced to Pfizer’s operations in Nigeria since 1957, before emerging as an independent pharmaceutical company in 1997 through a management buyout, inheriting manufacturing assets and brands from Pfizer.
Before the brand name Neimeth International Pharmaceuticals Plc., the company had operated in Nigeria for 40 years, manufacturing, marketing, and distributing Pfizer brands of pharmaceutical and veterinary products.
Today, the company specializes in two core business segments: pharmaceuticals and animal health. Its flagship product, Ciklavit, is a herbal extract for sickle cell crisis management, an in-house innovation reflecting Neimeth’s R&D capabilities, which by 2009 accounted for around 30% of its revenue.
Through the mid-2010s, Neimeth faced operational setbacks, including disruptive losses and a notable inventory fire. However, a recovery plan involving factory upgrades helped steer the company back to stability.
Management launched a five-year strategic plan (2025–2029) focused on cost-efficiency, expanded distribution, regional growth across Africa, and enhanced product development—setting the stage for sustainable expansion.
Neimeth’s stellar earnings recovery in recent years saw its share price jump alongside a 32% gain in early 2025, reflecting growing investor confidence. Despite challenges with forex volatility, mounting finance costs, and accumulated losses, Neimeth is reshaping its operations to achieve efficiency, restore profitability, and expand across regional markets.
